Latest News and Press Releases

The World Health Organization has approved “labafenogene marselecobac”Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria communityCAMBRIDGE, Mass., June...

CAMBRIDGE, Mass., June 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...

CAMBRIDGE, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reminded stockholders that it will...

Registrational study designed to support BLA submission of first-in-class biotherapeutic Company further streamlining organization to focus resources on execution of late clinical-stage programs in...

CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at...

CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that Aoife Brennan, M.B....

- Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – - Recent milestones include receipt of Rare Pediatric and Orphan Drug Designations from the FDA, and...

CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug...

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU)...

CAMBRIDGE, Mass., March 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the European Medicines...